HOME ABOUT US PRINT PUBLICATIONS SUBSCRIPTIONS CONTACT US RSS
 
Subscriber Sign In
 
Today@FDA
FDA Calendar
 
Archived Daily Updates
 
FDA Whistleblower
 
What do you think?
Search our 64,388-story database
Search
Renew subscription










E-mail This to a Friend | Print Format  
     
 
FDA Clears GenePOC Carba Assay
05/16/2019
 

FDA has cleared a GenePOC 510(k) for the Carba assay and its use with the Revogene device to detect carbapenem-producing organisms (CPO). CPOs are known to be resistant to commonly used antibiotics and occasionally completely resistant to all available antibiotics, the compamy says.

 

The qualitative, in vitro diagnostic test is designed for the detection and differentiation of the blaKPC, blaNDM, blaVIM, blaOXA-48-like, and blaIMP gene sequences associated with carbapenem-non-susceptibility, according to GenePOC. It says the assay can provide results for one to eight samples in about an hour using characterized carbapenem-non-susceptible pure colonies of Enterobacteriaceae, Acinetobacter baumannii, or Pseudomonas aeruginosa.

 

Revogene is an automated and stand-alone device, the company says, enabling testing of single-use proprietary microfluidic cartridges with fluorescence-based real-time polymerase chain reaction technology to deliver a diagnosis.


Post an instant comment on this report here

 
Any copying or electronic transfer without written permission is strictly prohibited and will result
in termination of service and prosecution under the federal Copyright Act.
To gain permission to copy this article log on to http://www.copyright.com.

FERDIC INCORPORATED - P.O. Box 28, Camp Hill, PA 17001 | Phone: (717)731-1426 fax:(717)731-1427 Email: info@fdaweb.com